Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260570 · ClinicalTrials.gov registry record · Early Phase 1
Remediation of Impaired Self-Regulation in Patients With Mild TBI
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
NCT02260570: Completed Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT02260570 is a Early Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02260570, a Early Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The ability to regulate impulses enables us to plan for the future, to maintain focus in the face of distractions (i.e. to encode memories), and to manage emotions. This self regulation can be compromised in individuals who have a history of mild traumatic brain injury and co-occurring disorders. In this study the investigators are using functional MRI scanning to understand how memory and self regulation are expressed in the brains of people with a history of mild traumatic brain injury. The investigators are also testing whether the medication tolcapone may improve memory and self regulation.
Interventions
- DRUG Placebo
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-08-01 |
| Est. Completion | 2021-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260570
The ClinicalTrials.gov registry entry for NCT02260570 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02260570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02260570 about?
NCT02260570 is a clinical study titled "Remediation of Impaired Self-Regulation in Patients With Mild TBI". The ability to regulate impulses enables us to plan for the future, to maintain focus in the face of distractions (i.e. to encode memories), and to manage emotions. This self regulation can be compromised in individuals who have a history of mild traumatic brain injury and co-occurring disorders. In...
What is the current status of trial NCT02260570?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2015-08-01. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT02260570?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT02260570?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.